Linda Stein Gold, MD, Director of Clinical Research and Division Head of Dermatology, Henry Ford Health in Detroit, MI, discusses the results of a post-hoc sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating the efficacy and safety of tapinarof cream, 1% (Vtama, Organon) vs. vehicle in atopic dermatitis patients (AD) patients down to age 2.
The aryl hydrocarbon receptor (AhR) agonist is approved for the treatment of plaque psoriasis in adults and atopic dermatitis (AD) in adults and pediatric patients aged 2 and up.
Dr. Stein Gold presented the study findings at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.
Tapinarof cream, 1% demonstrated early and consistent improvement in disease severity, as measured by vIGA-AD (Validated Investigator’s Global Assessment for Atopic Dermatitis), EASI (Eczema Area and Severity Index), and itch, as measured by Peak Pruritus Numerical Rating Scale (PP-NRS) for patients down to age 2 with moderate to severe AD.
In the ADORING 1 and ADORING 2 pivotal trials, adults and children ≥2 years (N=813) with moderate-to-severe AD were randomized to tapinarof cream, 1% or vehicle once daily for 8 weeks.
Significant improvements in vIGA-AD, EASI-75, and PP-NRS response rates were noted as early as Week 1
Significant vIGA-AD response was observed, defined as Clear (vIGA-AD=0) or Almost Clear (vIGA-AD=1) skin with a ≥2-grade improvement from baseline, as early as Week 1 (5.8% vs. 1.6%, P=0.0315) and continued through Week 8 (45.9% vs. 15.9%).
Significant EASI-75 response was achieved as early as Week 1 (9.0% vs. 3.3%, P=0.0164) and continued through Week 8 (57.4% vs 22.1%).
Significant itch improvement, defined as a ≥4-point reduction in PP-NRS score for patients with a baseline score of ≥4, was achieved as early as Week 1 (18.8% vs. 11.3%) and continued through Week 8 (59.3% vs. 33.5%). The vast majority (96.9%) of patients achieved any EASI improvement from baseline at Week 8 with tapinarof cream, 1%.
Consistent with the prescribing information, tapinarof cream, 1% was well-tolerated, with the most frequently reported (≥3% in any group) treatment-emergent adverse events being folliculitis, headache, upper respiratory tract infection, and nasopharyngitis.